Belzutifan is a selective inhibitor of HIF-2. It’s used for treating RCC that’s linked to VHL disease. The drug blocks the HIF-2 protein.
This protein is key for RCC cells to survive in low-oxygen situations. Blocking it helps reduce tumor hypoxia signals. It’s taken by mouth and comes in tablets that are coated and each one is 40 mg.
You’re supposed to take 120 mg once a day, which is three tablets. The med comes in bottles that hold 90 tablets each.
